New two-drug combo aims to wipe out HER2 breast cancer before surgery
Disease control
Ongoing
This phase 3 trial compares a new drug combination (KN026 plus HB1801, with or without carboplatin) against the standard treatment (trastuzumab, pertuzumab, and docetaxel, with or without carboplatin) in people with early or locally advanced HER2-positive breast cancer. The goal …
Phase: PHASE3 • Sponsor: Shanghai JMT-Bio Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC